Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Final analysis results from the CLL11 study (NCT01010061) were presented at the press briefing by Dr Valentin Goede, of the German CLL Study Group, Cologne, Germany. Dr Goede highlights the overall survival benefit of obinutuzumab plus chlorambucil over rituximab in patients with chronic lymphocytic leukemia (CLL) and comorbidities.
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
